
© Food Freedom News
The US Food & Drug Admin. just
approved a drug made from genetically modified carrots to treat Gaucher, a rare disease found mostly among Ashkenazi Jews. Out of a global population of 6.8 billion, an estimated range of 60-100,000 people carry the recessive gene for it, though not all are symptomatic.
The incidence of Gaucher is so rare, in fact, that to approve a GMO carrot for this purpose makes no sense, raising the specter of some unstated plan.
As expected when humans ingest active foreign DNA, one of the side effects of the FDA-approved drug, Elelyso®, is anaphylactic shock, among other allergic reactions.
Gaucher develops in offspring of parents who both carry and pass on a recessive gene that prevents development of an enzyme that allows "harmful substances to build up in the liver, spleen, bones, and bone marrow," explains the
A.D.A.M. Medical Encyclopedia. "The substances prevent cells and organs from working properly."
The recessive gene only appears in
6-10 percent of Ashkenazi Jews, who number just over
10 million today.
Several rare genetic diseases are linked to Ashkenazi Jews, who account for 80 percent of all Jews, reports the
Hebrew University of Jerusalem, "including Tay-Sachs, Gaucher disease, Bloom syndrome, Idiopathic torsion dystonia, Familial dysautonomia, Factor XI deficiency, and more. For many of these disorders in which a causative gene has been identified, a specific mutation was found to be the cause of most cases of the disease in Ashkenazi Jews."
Dr. Mercola reacted with shock to the news,
writing, "I don't even want to think about the potential ramifications of this decision. Many may not know this, but Monsanto, well-known as the leader in biotechnology and genetically engineered foods, is also invested in the medical industry."